• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白质-金属药物相互作用:对整体蛋白质结构的影响及 Au、Ru 和 Pt 结合部位的表征。

Protein-metallodrugs interactions: Effects on the overall protein structure and characterization of Au, Ru and Pt binding sites.

机构信息

Department of Chemical Sciences, University of Naples Federico II, Naples, Italy.

Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy.

出版信息

Int J Biol Macromol. 2020 Nov 15;163:970-976. doi: 10.1016/j.ijbiomac.2020.07.053. Epub 2020 Jul 10.

DOI:10.1016/j.ijbiomac.2020.07.053
PMID:32653380
Abstract

The effects of metalation process by inorganic compounds containing Au, Pt and Ru on protein structure and on conformation and flexibility of the residues involved in the metal compound binding have been here investigated by analysing 204 structures of protein/metallodrug adducts and the corresponding metal-free forms. The overall structure of the proteins is not significantly affected by the metal label. 162 non-redundant protein residues involved in Au, Pt and Ru coordination have been identified. In the metal-free protein structures these residues often belong to α-helical regions and show low flexibility. They do not necessarily belong to outer layers of the protein structure. In the majority of the adducts, the side chains of these residues adopt a conformation that is similar to that observed in the metal-free protein. The metal coordination reduces their solvent accessible surface area without altering their overall flexibility. These results could be useful for the prediction of residues able to bind Au, Pt and Ru compounds.

摘要

本研究通过分析 204 个蛋白/金属药物加合物结构及其相应的无金属形式,考察了含 Au、Pt 和 Ru 的无机化合物的金属化过程对蛋白结构以及金属化合物结合部位残基的构象和柔韧性的影响。金属标签并未显著影响蛋白的整体结构。鉴定出 162 个非冗余参与 Au、Pt 和 Ru 配位的蛋白残基。在无金属蛋白结构中,这些残基通常属于α-螺旋区域,柔韧性较低。它们不一定属于蛋白结构的外层。在大多数加合物中,这些残基的侧链采取与无金属蛋白中观察到的相似的构象。金属配位降低了它们的溶剂可及表面积,而不改变其整体柔韧性。这些结果可用于预测能够结合 Au、Pt 和 Ru 化合物的残基。

相似文献

1
Protein-metallodrugs interactions: Effects on the overall protein structure and characterization of Au, Ru and Pt binding sites.蛋白质-金属药物相互作用:对整体蛋白质结构的影响及 Au、Ru 和 Pt 结合部位的表征。
Int J Biol Macromol. 2020 Nov 15;163:970-976. doi: 10.1016/j.ijbiomac.2020.07.053. Epub 2020 Jul 10.
2
Photophysical properties of ruthenium(II) polypyridyl-gold(I) ethynyl dyads and triads containing mono- or diethynylphenanthroline incorporated into gold(I) triphenylphosphine organometallics.钌(II)多吡啶-金(I)炔基偶联物和三联体的光物理性质,其中包含单或二炔基菲咯啉与金(I)三苯基膦有机金属化合物的结合。
Inorg Chem. 2010 May 3;49(9):4186-93. doi: 10.1021/ic902417m.
3
Recent advances in protein metalation: structural studies.蛋白质金属化的最新进展:结构研究。
Chem Commun (Camb). 2021 Feb 11;57(11):1295-1307. doi: 10.1039/d0cc08053e.
4
DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.单功能有机金属钌(II)抗肿瘤复合物在无细胞培养基中的DNA相互作用
Biochemistry. 2003 Oct 7;42(39):11544-54. doi: 10.1021/bi034933u.
5
Metal-metal interactions in platinum(II)/gold(I) or platinum(II)/silver(I) salts containing planar cations and linear anions.含平面阳离子和线性阴离子的铂(II)/金(I)或铂(II)/银(I)盐中的金属-金属相互作用
Inorg Chem. 2005 May 16;44(10):3466-72. doi: 10.1021/ic048333a.
6
Caged noble metals: Encapsulation of a cytotoxic platinum(II)-gold(I) compound within the ferritin nanocage.笼状贵金属:细胞毒性的铂(II)-金(I)化合物被包裹在铁蛋白纳米笼内。
Int J Biol Macromol. 2018 Aug;115:1116-1121. doi: 10.1016/j.ijbiomac.2018.04.142. Epub 2018 Apr 30.
7
Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.抗癌金属药物与选定蛋白质之间形成的加合物的生物物理特性:来自X射线衍射和质谱研究的新见解。
J Inorg Biochem. 2008 May-Jun;102(5-6):995-1006. doi: 10.1016/j.jinorgbio.2007.12.022. Epub 2008 Jan 8.
8
Cellular transport mechanisms of cytotoxic metallodrugs: an overview beyond cisplatin.细胞毒性金属药物的细胞转运机制:顺铂之外的概述
Molecules. 2014 Sep 29;19(10):15584-610. doi: 10.3390/molecules191015584.
9
Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.有机金属钌(II)二胺抗癌配合物:鸟嘌呤加合物中的芳烃-核碱基堆积和立体特异性氢键作用
J Am Chem Soc. 2002 Mar 27;124(12):3064-82. doi: 10.1021/ja017482e.
10
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.通过质谱法探索金属药物与蛋白质的相互作用:铂配位络合物与有机金属钌化合物的比较
J Biol Inorg Chem. 2009 Jun;14(5):761-70. doi: 10.1007/s00775-009-0489-5. Epub 2009 Mar 14.

引用本文的文献

1
A Diruthenium Metallodrug as a Potent Inhibitor of Amyloid-β Aggregation: Synergism of Mechanisms of Action.一种双钌金属药物作为淀粉样β聚集的有效抑制剂:作用机制的协同作用。
Inorg Chem. 2024 Jan 8;63(1):564-575. doi: 10.1021/acs.inorgchem.3c03441. Epub 2023 Dec 20.
2
Cross-Linked Crystals of Dirhodium Tetraacetate/RNase A Adduct Can Be Used as Heterogeneous Catalysts.交联的二钌四乙酸/RNaseA 加合物晶体可用作多相催化剂。
Inorg Chem. 2023 May 15;62(19):7515-7524. doi: 10.1021/acs.inorgchem.3c00852. Epub 2023 May 5.
3
Protein-Based Delivery Systems for Anticancer Metallodrugs: Structure and Biological Activity of the Oxaliplatin/β-Lactoglobulin Adduct.
用于抗癌金属药物的基于蛋白质的递送系统:奥沙利铂/β-乳球蛋白加合物的结构与生物活性
Pharmaceuticals (Basel). 2022 Mar 30;15(4):425. doi: 10.3390/ph15040425.
4
Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.线粒体损伤铂(IV)前药与细胞色素 c 的相互作用。
Dalton Trans. 2022 Feb 1;51(5):2012-2018. doi: 10.1039/d1dt03875c.
5
Reactions with Proteins of Three Novel Anticancer Platinum(II) Complexes Bearing N-Heterocyclic Ligands.三种新型含氮杂环配体抗癌铂(II)配合物与蛋白质的反应。
Int J Mol Sci. 2021 Sep 29;22(19):10551. doi: 10.3390/ijms221910551.